Publications

Skip to content

New and Noteworthy

Explore our latest insights, research, and stories

Genitourinary cancer research is incredibly promising, and real-world evidence is a key part of it

Real-world evidence
Case study
Prostate cancer
Genitourinary cancer

Powering a new era of treatment with real-world insights on >26K people with ovarian cancer
Flatiron Health announces research to be presented at ISPOR 2025
With real-world evidence, the whole is greater than the sum of its parts
- Real-world evidence
- Case study

Featured topics

Real-world evidence
Clinical research
Point of care
Flatiron stories
Clinical decision support
Video
Machine learning
Press releases
Post marketing requirements
HTA and market access
Health equity
Case study
EHR-to-EDC

All the latest

Topics

Artificial intelligence

Clinical decision support

Clinical research

Inclusion

Data management

Drug Discovery

EHR-to-EDC

Flatiron stories

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Patient identification

Point of Care

Post marketing requirements

Practice management

Precision medicine

Prospective study

Protocol optimization

Real-World Evidence

Regulatory

Site identification

Technology & Engineering

Treatment patterns

Trial design

Unmet need

Value-based care

Content type

Article

Press releases

Case study

Publications

Customer interviews

Event recap

Video

Podcast

Showing 9 of 0 results

How to incorporate pragmatic design elements into your clinical studies
Genitourinary cancer research is incredibly promising, and real-world evidence is a key part of it
Powering a new era of treatment with real-world insights on >26K people with ovarian cancer
The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Cancer
Flatiron Health announces research to be presented at ISPOR 2025
Using regression discontinuity in time design for real-world comparative effectiveness: A case study for the second-line use of pembrolizumab in advanced non-small cell lung cancer
ISPOR 2025
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
Blood Cancer Journal
With real-world evidence, the whole is greater than the sum of its parts
- Real-world evidence
- Case study
From data to decisions: the role of real-world evidence in recent multiple myeloma drug approvals in the US and EU
ISPOR

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Clinical Research
Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Data Confidentiality Commitments
Cookie Settings
© FLATIRON HEALTH® 2025